---
document_datetime: 2026-01-16 12:32:32
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ifirmacombi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ifirmacombi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5785638
conversion_datetime: 2026-01-17 13:42:06.696493
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ifirmacombi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 15/01/2026                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308442                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - to update section 5.3 of the SmPC to shorten/update the information on irbesartan monocomponent and the combination irbesartan/hydrochlorothiazide following assessment of the same changes for the parent product CoAprovel ((EMEA/H/C/ 000222/VR/0000265130). In addition, the MAH made also some editorial amendments in national PIs to bring them in line with the same translation of the reference product or to align with the QRD   |            |             |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IB / EMA/VR/0000258252 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 08/05/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| PRODUCTS - C.I.z Other variation - Accepted C.I.z - To update sections 4.4 and 4.8 of the SmPC with new safety information regarding intestinal angioedema following PRAC recommendations on signals adopted on 31 October 2024. Sections 2 and 4 of the Package Leaflet were updated accordingly. In addition, the MAH took the opportunity to include minor editorial corrections in the following languages: EN, CS, DA, ES, FI, HU, IT, LV, NO, RO and SL. Finally, for Ifirmacombi only, the information related to the local representatives for Hungary was updated and (UK) Northern Ireland local representative was deleted in section 6 of the Package Leaflet according to the latest QRD template update 10.4.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|